Cardiovascular morbidity in long-term survivors of metastatic testicular cancer

Author(s): Meinardi MT, Gietema JA, Van-der GWT, Van-Veldhuisen DJ, Runne MA, et al.

Abstract

PURPOSE: To determine whether long-term survivors of metastatic testicular cancer have an increased risk of cardiovascular morbidity more than 10 years after chemotherapy.

PATIENTS AND METHODS: Eighty-seven patients treated with cisplatin-containing chemotherapy before 1987 who were in remission for at least 10 years and whose ages were ≤ 50 years at the time of analysis were evaluated for the occurrence of cardiovascular events. Sixty-two of 87 patients were additionally evaluated for cardiac damage and cardiovascular risk factors. Their cardiovascular risk profile was compared with that of 40 patients with comparable age and follow-up duration treated with orchidectomy only for stage I disease.

Similar Articles

Acute aortic thrombosis in patients receiving cisplatin-based chemotherapy

Author(s): Fernandes DD, Louzada ML, Souza CA, Matzinger F

Cardiotoxicity of cytotoxic drugs

Author(s): Schimmel K, Richel D, Van-Den BRB, Guchelaar HJ

Lung cancer as a cardiotoxic state:a rewiev

Author(s): Pérez-Callejo D, Torrente M, Brenes MA, Núñez B, Provencio M

Characterization of cardiovascular alterations induced by different chronic cisplatin treatments

Author(s): Herradón E, González C, Uranga JA, Abalo R, Martín MI, et al.

Cisplatin-induced cardiotoxicity– two case reports

Author(s): Sawant J, Prakruthi AD, Daddi J, Ghosh A, Joshi A, et al.

Cardiovascular toxicity induced by chemotherapy,targeted agents and radiotherapy: ESMO Clinical Practice Guidelines

Author(s): Curigliano G, Cardinale D, Suter T , Plataniotis G, De Azambuja E, et al.